NC-KBI-BIOPHARM/ARGONAUT
16.1.2024 13:58:26 CET | Business Wire | Press release
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), and Argonaut Manufacturing Services, Inc. (Argonaut), a cGMP contract manufacturing organization (CMO) serving the biopharmaceutical and diagnostics industries, today announced a strategic alliance offering biopharmaceutical clients with end-to-end drug substance and drug product manufacturing solutions. The arrangement provides a seamless integration of drug substance and drug product manufacturing by combining KBI’s leading drug development and biologics manufacturing services with Argonaut’s expertise in sterile fill-finish. The alliance reinforces both companies’ commitment to support customers in bringing clinical and commercial therapies to patients quickly, safely, and efficiently.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240116635207/en/
Biopharmaceutical organizations are expected to benefit from this strategic collaboration through accelerated timelines and the scalable manufacturing capacities offered by both organizations.
“At KBI Biopharma, we have always been committed to delivering innovative solutions that accelerate the development and manufacturing of life-saving therapeutics. Our state-of-the-art facilities and world-class team have consistently pushed the boundaries of what is possible in biopharmaceutical development,” said J.D. Mowery, President and CEO of KBI Biopharma.
He continued, “Similarly, Argonaut has established itself as a trusted provider in the industry, known for its cutting-edge technologies and exceptional track record in drug product manufacturing. Their commitment to quality and efficiency aligns perfectly with our own values and vision. This collaboration represents a new era of collaboration and innovation in the biopharma industry.”
“We believe this strategic alliance resolves a key issue for biopharmaceutical organizations as it greatly improves the alignment and integration between two complex and critical aspects of drug development and manufacturing. Biopharmaceutical companies will benefit from an integrated solution that is faster, more flexible, and leverages the unique expertise of our two organizations,” said Wayne Woodard, Founder and CEO of Argonaut. “Argonaut’s fill-finish capabilities are scalable from first-in-human clinical material for rare diseases through commercial batches of approved products. With this collaboration, biopharmaceutical organizations can now seamlessly move from development to full-scale manufacturing, saving both time and capital expenditures.”
In January 2023, Argonaut announced a capital investment focused on the significant expansion of its Carlsbad, CA manufacturing facilities with increased capacity and scale, and this agreement with KBI furthers its commitment to continual growth.
About Argonaut Manufacturing Services, Inc.
Argonaut Manufacturing Services is an FDA-registered cGMP contract manufacturing organization (CMO) dedicated to providing custom manufacturing and supply chain solutions for biopharmaceutical and diagnostic companies. Aseptic drug fill/finish features state-of-the-art automated equipment for high-yield filling of sterile injectable drugs including biologics, peptides, small molecule, and vaccines. Diagnostic manufacturing includes proprietary lyophilization technology and a spectrum of kitting capabilities. Projects are supported with full analytical quality control services including warehousing and global shipping logistics. Serving innovators in the life science, molecular diagnostics, and biopharma industries, Argonaut provides a wide range of flexible solutions for diverse outsourcing needs.
More information available at www.argonautms.com.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240116635207/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sparxity Closes Series A, Bringing Total Funding to $90M10.11.2026 14:00:00 CET | Press release
Strategic funding accelerates next-generation sparse-native AI computing, building upon an existing commercial ecosystem and proven silicon Sparxity, a leader in sparse-native computing, today announced the close of its Series A, bringing cumulative funding secured by its team to $90M. The round was led by ICM HPQC Fund and joined by investors such as Lockheed Martin Ventures, GlobalFoundries, GS Futures, Cloudberry Ventures, TGFS and the EIC Fund. The financing also includes angel investments from TIME100 AI leaders Richard Socher (Recursive Superintelligence) and Nancy Xu (Salesforce-acquired Moonhub), alongside continued support from Atlantic and Silicon Catalyst. The funding will accelerate the development of specialized chips for fine-grained dynamic sparsity, targeting up to 44× faster AI inference in ultra-sparse models, bringing greater energy efficiency by computing only what matters. This press release features multimedia. View the full release here: https://www.businesswire.
Transition Industries Selects Technip Energies as PMC Partner for Pacifico Mexinol Ultra-Low Carbon Methanol Project10.11.2026 14:00:00 CET | Press release
Transition Industries announces the selection of Technip Energies as its Project Management Consultancy (PMC) partner for the Pacifico Mexinol project, located in Sinaloa, Mexico, which is expected to become the world's largest ultra-low carbon chemical production facility. Once operational, the facility will produce annually approximately 350,000 metric tons of RFNBO (Renewable Fuel of Non-Biological Origin) methanol and 1.8 million metric tons of ultra-low carbon methanol from natural gas with carbon capture, helping meet growing global demand through a lower-carbon production model. “We are pleased that Technip Energies has joined the project team and will bring their global project management expertise to our landmark industrial development project in Mexico. Technip Energies was selected for their project management expertise, technical know-how and execution capabilities,” says Diego Martinez, Transition Industries Chief Operating Officer. The project will use existing infrastruc
Telia Estonia trials Adtran 50G PON technology to prepare for next-generation broadband services10.11.2026 14:00:00 CET | Press release
News summary: Telia Estonia is preparing its fiber network to support the next generation of residential and business broadband services Trial of Adtran’s 50G PON solution establishes a practical path to higher-capacity access over existing infrastructure Project will validate how 50G PON can operate alongside GPON and XGS-PON services, enabling phased network upgrades Adtran today announced that Telia Estonia, part of Nordic and Baltic telecommunications operator Telia Company, is trialing its 50G PON technology as the next step in the evolution of its fiber broadband infrastructure. Building on its deployment of Adtran’s fiber access platform, the proof of concept (PoC) will evaluate how 50G PON can coexist with existing GPON and XGS-PON services on a common network infrastructure. The trial will help Telia Estonia prepare for future residential and business connectivity requirements while providing a practical framework for introducing higher-capacity services as market needs develo
Vasion® Fall Release Eliminates Dark Documents and Makes Operational Documents AI Ready10.11.2026 14:00:00 CET | Press release
New release puts AI agents, workflows and print into one control center for IT IT-Governed Document AI: Vasion Intelligence (beta) lets IT set guardrails up front while empowering users to easily create human in the loop workflows. Zero Trust Gap: A survey of 500+ U.S. IT leaders reveals print ranks last in Zero Trust coverage at just 16%. Live at Microsoft Ignite: Demos and benchmarking will run November 17–21 at Booth 5509. Vasion, the Intelligent Document Automation company, announced its fall release, which captures the context behind operational documents and makes them ready for AI without IT giving up control. Vasion will demonstrate it at Microsoft Ignite, November 17-21, in San Francisco, booth 5509. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261110362305/en/ Vasion® Fall Release Eliminates Dark Documents and Makes Operational Documents AI Ready “Every company runs on operational documents: the invoices, claims,
Nebul Adopts NetApp Novus to Power Sovereign AI Infrastructure10.11.2026 14:00:00 CET | Press release
Neocloud pioneer selects the fastest storage on the planet, NetApp Novus, architected to enable its file system to grow to support zettabyte-scale AI factory operations NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that Nebul, a European AI-native cloud provider, is the first neocloud to adopt NetApp Novus™, its new high-performance architecture designed to deliver the fastest storage on the planet. Nebul is building the Intelligent Cloud, a sovereign platform integrating accelerated infrastructure, enterprise data services and production AI capabilities. Novus, now generally available, is designed to maximize utilization for millions of GPUs and is architected for up to 100 TB per second of aggregate throughput. Moving quickly to adopt the groundbreaking technology, Nebul and NetApp are exploring new opportunities to help organizations achieve AI-powered advantage and unlock greater value from their data. Bringing together Nebul’s sovereign AI se
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom